JP2025084850A5 - - Google Patents
Info
- Publication number
- JP2025084850A5 JP2025084850A5 JP2025029451A JP2025029451A JP2025084850A5 JP 2025084850 A5 JP2025084850 A5 JP 2025084850A5 JP 2025029451 A JP2025029451 A JP 2025029451A JP 2025029451 A JP2025029451 A JP 2025029451A JP 2025084850 A5 JP2025084850 A5 JP 2025084850A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- adenovirus
- nucleic acid
- subject
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1910804.2A GB201910804D0 (en) | 2019-07-29 | 2019-07-29 | Hantavirus antigenic Composition |
| GB1910804.2 | 2019-07-29 | ||
| JP2022506337A JP7642608B2 (ja) | 2019-07-29 | 2020-07-29 | ハンタウイルス抗原性組成物 |
| PCT/GB2020/051813 WO2021019235A2 (en) | 2019-07-29 | 2020-07-29 | Hantavirus antigenic composition |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506337A Division JP7642608B2 (ja) | 2019-07-29 | 2020-07-29 | ハンタウイルス抗原性組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025084850A JP2025084850A (ja) | 2025-06-03 |
| JP2025084850A5 true JP2025084850A5 (https=) | 2025-10-06 |
Family
ID=67990345
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506337A Active JP7642608B2 (ja) | 2019-07-29 | 2020-07-29 | ハンタウイルス抗原性組成物 |
| JP2025029451A Pending JP2025084850A (ja) | 2019-07-29 | 2025-02-26 | ハンタウイルス抗原性組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506337A Active JP7642608B2 (ja) | 2019-07-29 | 2020-07-29 | ハンタウイルス抗原性組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220275346A1 (https=) |
| EP (1) | EP4003413A2 (https=) |
| JP (2) | JP7642608B2 (https=) |
| KR (1) | KR20220038755A (https=) |
| CN (2) | CN114269939B (https=) |
| GB (1) | GB201910804D0 (https=) |
| WO (1) | WO2021019235A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113234129B (zh) * | 2021-05-08 | 2023-02-07 | 中国人民解放军空军军医大学 | Hla-e限制性htnv结构蛋白特异性cd8+t细胞表位肽及其聚合物和应用 |
| US20250127870A1 (en) * | 2021-09-16 | 2025-04-24 | Board Of Regents, The University Of Texas System | mRNA Vaccines Against Hantavirus |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4473497A (en) * | 1996-10-04 | 1998-04-24 | Cheil Jedang Corporation | Nucleocapsid gene of seoul virus r22, recombinant plasmid, transformed e. coli and diagnostic agent and vaccine for haemorrhagic fever with renal syndrome |
| DE60029928D1 (de) | 1999-01-29 | 2006-09-21 | U S Medical Res Inst Of Infect | Dna impfstoffe gegen hantavirus infektionen |
| CN101163498B (zh) | 2004-06-18 | 2011-10-05 | 诺华疫苗和诊断公司 | 用于诊断汉他病毒感染的方法和试剂 |
| WO2006022461A1 (en) | 2004-08-27 | 2006-03-02 | Nexgen Biotechnologies, Inc. | Diagnosis kits for hemorrhagic fever with renal syndrome comprising nucleocapsid protein of hanta virus expressed in transformed plant |
| US11602557B2 (en) * | 2017-08-22 | 2023-03-14 | Cure Vac SE | Bunyavirales vaccine |
-
2019
- 2019-07-29 GB GBGB1910804.2A patent/GB201910804D0/en not_active Ceased
-
2020
- 2020-07-29 EP EP20751639.4A patent/EP4003413A2/en active Pending
- 2020-07-29 CN CN202080054858.XA patent/CN114269939B/zh active Active
- 2020-07-29 US US17/631,416 patent/US20220275346A1/en active Pending
- 2020-07-29 WO PCT/GB2020/051813 patent/WO2021019235A2/en not_active Ceased
- 2020-07-29 KR KR1020227006458A patent/KR20220038755A/ko active Pending
- 2020-07-29 CN CN202411481536.XA patent/CN119144656A/zh active Pending
- 2020-07-29 JP JP2022506337A patent/JP7642608B2/ja active Active
-
2025
- 2025-02-26 JP JP2025029451A patent/JP2025084850A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025084850A5 (https=) | ||
| CN100379865C (zh) | 用于产生cd8t细胞免疫应答的试剂盒及其用途 | |
| JP6505016B2 (ja) | 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答 | |
| JP2014516536A5 (https=) | ||
| KR20090005010A (ko) | Ｈｐｖ-18-기재의 유두종바이러스 백신 | |
| Greiner et al. | The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity | |
| CA2388301A1 (en) | Modified gp100 and uses thereof | |
| JP2018524977A5 (https=) | ||
| JP2024105526A5 (https=) | ||
| Legrand et al. | Vaccinia viruses with a serpin gene deletion and expressing IFN-γ induce potent immune responses without detectable replication in vivo | |
| WO2019214110A1 (zh) | 一种以人复制缺陷腺病毒为载体的马尔堡病毒病疫苗 | |
| JP2021528367A5 (https=) | ||
| Marín-López et al. | Generation of recombinant modified vaccinia virus Ankara encoding VP2, NS1, and VP7 proteins of bluetongue virus | |
| Mozharovskaya et al. | Development and characterization of a vector system based on the simian adenovirus type 25 | |
| JP2022547786A5 (https=) | ||
| WO2006061643A1 (en) | Method for vaccinating usign a prime-boost regime and hsv as a vector | |
| CN102086453B (zh) | 以粘蛋白1和生存素为靶点的肿瘤dna疫苗及病毒载体疫苗 | |
| JP2019528271A5 (https=) | ||
| US20240261350A1 (en) | Adenovirus for anti-tumour therapy | |
| CN118652355A (zh) | 靶向psma的嵌合抗原受体及其修饰的细胞和应用 | |
| CN101670102A (zh) | 联合使用痘病毒载体hiv疫苗与腺病毒载体hiv疫苗的方法及其应用 | |
| Chen et al. | Primary adenovirus-specific cytotoxic T lymphocyte response occurs after viral clearance and liver enzyme elevation | |
| US20220118081A1 (en) | HIV vaccine regimens | |
| AU775973B2 (en) | Methods and reagents for vaccination which generate a CD8 T cell immune response | |
| Chamberlain et al. | THE USE OF RECOMBINANT POXVIRUSES AS A PARADIGM FOR THE DEVELOPMENT OF ANTI-CANCER VACCINES |